Halozyme Therapeutics, Inc.HALONASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank97
3Y CAGR+57.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+57.8%/yr
vs +33.8%/yr prior
Acceleration
+24.0pp
Accelerating
Percentile
P97
Near historical high
vs 3Y Ago
3.9x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 37.41% |
| Q3 2025 | 10.75% |
| Q2 2025 | -1.77% |
| Q1 2025 | 0.27% |
| Q4 2024 | 2.44% |
| Q3 2024 | 15.49% |
| Q2 2024 | 1.64% |
| Q1 2024 | -6.58% |
| Q4 2023 | 6.63% |
| Q3 2023 | -9.45% |
| Q2 2023 | 4.26% |
| Q1 2023 | -1.04% |
| Q4 2022 | 9.52% |
| Q3 2022 | -40.03% |
| Q2 2022 | 315.47% |
| Q1 2022 | 0.44% |
| Q4 2021 | 4.59% |
| Q3 2021 | 6.88% |
| Q2 2021 | 11.41% |
| Q1 2021 | 6.06% |
| Q4 2020 | -10.90% |
| Q3 2020 | 6.62% |
| Q2 2020 | -13.12% |
| Q1 2020 | -47.21% |
| Q4 2019 | 33.09% |
| Q3 2019 | 3.70% |
| Q2 2019 | -3.71% |
| Q1 2019 | -0.14% |
| Q4 2018 | 21.31% |
| Q3 2018 | 3.56% |
| Q2 2018 | 5.88% |
| Q1 2018 | -8.23% |
| Q4 2017 | 10.82% |
| Q3 2017 | 1.74% |
| Q2 2017 | 3.85% |
| Q1 2017 | 3.17% |
| Q4 2016 | 5.41% |
| Q3 2016 | 3.37% |
| Q2 2016 | 3.84% |
| Q1 2016 | 2.05% |